RFA-ES-25-001: Epitranscriptomics Crosstalks and Toxicants (EPCOT) (R01 Clinical Trials Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants of up to $500,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on February 6, 2025.
From the official notice on Grants.gov, last changed November 14, 2024. Checked November 7, 2026.
- Award ceiling$500,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIEHS
- Median yearly award$742,711
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-ES-25-001 were run by National Institute of Environmental Health Sciences (NIEHS, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-ES-25-001 in the NIH Guide.
Key dates
| Posted | November 14, 2024 |
|---|---|
| Deadline | February 6, 2025 |
| Archived by Grants.gov | March 14, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $742,711; it allows up to $500,000 per award.
- Most of the program's money (81% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this initiative is to solicit new R01 applications that propose innovative studies to explore how exposures to environmental toxicants may inhibit, create new or otherwise impact epitranscriptomic crosstalks and provide mechanistic insights into how these interactions play a role in initiation, progression, and/or exacerbation of adverse health outcomes. Epitranscriptomic crosstalks are defined as interactions between epitranscriptomic marks and associated Readers Writers and Erasers (RWEs) and epigenomic marks and/or epigenomic RWEs, and genomic structures.
Funded under RFA-ES-25-001 so far
NIH funded 6 projects under RFA-ES-25-001 in fiscal 2026, at 5 institutions. The median yearly award was $742,711.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Epitranscriptomic and Epigenetic Loops Driving the Response to Naphthalene | State University of New York at Albany | 2026 | $814,154 |
| Interplay between TET1-mediated epigenomic mechanisms and m6A RNA modification in pulmonary inflammation induced by particulate matter | University of California at Davis | 2026 | $749,640 |
| Investigation of epitranscriptomic crosstalks related to autism using real patients and brain organoids | Florida International University | 2026 | $772,659 |
| Molecular Mechanisms of Epitranscriptomic Dysregulation Induced by Toxic Metals | UT Southwestern Medical Center | 2026 | $649,193 |
| Crosstalk of Epitranscriptomic RNA Modifications and DNA Damage Repair | Florida International University | 2026 | $489,258 |
| Chromatin regulation through RNA demethylation in environmental stress response | University of Chicago | 2026 | $735,782 |
Who has won Environmental Health grants before
From fiscal 2021 to 2025, Environmental Health (93.113) awarded $2.1 billion across 1,980 grant awards, an average of $1.1 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | 49 | $87.7 million |
| The Trustees of Columbia University in the City of New York | New York | 69 | $78.7 million |
| University of North Carolina at Chapel Hill | North Carolina | 59 | $71.5 million |
| Emory University | Georgia | 57 | $67.2 million |
| University of Southern California | California | 40 | $58.9 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-ES-25-001 still open?
No. It closed on February 6, 2025.
Who can apply for Epitranscriptomics Crosstalks and Toxicants (EPCOT) (R01 Clinical Trials Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Epitranscriptomics Crosstalks and Toxicants (EPCOT) (R01 Clinical Trials Not Allowed)?
Closed February 6, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each.
Who has been funded under RFA-ES-25-001?
NIH RePORTER lists 6 projects funded under RFA-ES-25-001 in fiscal 2026, at 5 institutions. The most were at Florida International University, State University of New York at Albany, University of California at Davis.
Who has won Environmental Health grants before?
The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)